EGFR and non-small cell lung carcinoma: While the EGFR TKIs erlotinib, afatinib, gefitinib, dacomitinib, and osimertinib are FDA-approved for the treatment of patients with non-small cell lung harboring select EGFR-mutations such as G719A, their clinical utility in patients with EGFR L833_V834delinsFL altered NSCLC is unknown.